BRD4 and melanoma: Although BET inhibitors show limited selectivity due to the inability to discriminate between the BD1 and BD2 bromodomains across the BET family members, which are overexpressed in melanoma cells, we confirmed our data with the recently developed MZ1, a PROTAC chimera that links JQ1 to a ligand for the E3-ubiquitin ligase VHL, rapidly inducing enduring and preferential removal of BRD4 over BRD2 and BRD3 [13, 14].